Piloting a Healthy Aging Cohort in Manitoba (PACMan)

November 21, 2025 updated by: Claudio Rigatto, University of Manitoba

Piloting a Healthy Aging Cohort in Manitoba - PACMan

The purpose of this study is to set up and pilot baseline data collection for a prospective cohort designed to explore the relationships between medical fitness facility usage, lifestyle behaviours and health outcomes as individuals age. Additionally, this pilot study will set up the overall objectives for the larger, prospective cohort study using a public engagement participatory approach with public/patient partners involved in determining which healthy aging outcomes to include.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This project will cover the set-up, development, and user-testing of the baseline visit data collection in the first 100 participants. Data will be collected on physical activity, diet, sleep, stress, cognition, frailty, health history (including diabetes, alcohol and smoking), facility and program usage at the Wellness Institute (WI), height, weight, volitional oxygen intake (VO2 max), blood pressure, heart rate, clinical chemistry, urinalysis, body composition, social determinants of health, and wellbeing.

Additionally, a public engagement participatory approach will be used to determine which healthy aging outcomes are important to study, including discussion on research priorities, research question, research design, data collection approaches, outcome measures, analysis of results, relevance of findings, and dissemination of findings. Therefore, this pilot project will include the formation of a project advisory group that will include public/patient partners. The advisory group members will discuss ideas around healthy aging and lifestyle and what outcomes are most important to them; and will provide information on the reasons for joining as well as the use of the medical fitness facility, any barriers they face and program needs. The project advisory group will be an integral part of this pilot project. The information obtained from the advisory group meetings and the pilot project will be used to develop the outcomes for the larger cohort study.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Manitoba
      • Winnipeg, Manitoba, Canada, R2V 3M3
        • Recruiting
        • Seven Oaks Hospital Chronic Disease Innovation Centre
        • Contact:
        • Principal Investigator:
          • Clara Bohm, MD, MPH
        • Contact:
        • Principal Investigator:
          • Claudio Rigatto, MD, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Participants will be recruited from individuals that attend The Wellness Institute. This study is a pilot with the number of recruited participants set as the initial 20 plus an additional anticipated 80, totaling 100 participants.

Description

Inclusion Criteria:

  • Male or female, aged 30 years or above.
  • Able to communicate in English and provide written informed consent
  • Current member of the Wellness Institute
  • Access to a device such as an android or iOS smartphone or tablet for use with the dietary tracking application.

Exclusion Criteria:

  • Female participant who is pregnant or lactating
  • Employees of the Wellness Institute
  • Involvement in the planning and/or conduct of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health History
Time Frame: At baseline an Year 1
Collected using the Chronic Conditions, Health History and Facility Usage Questionnaire and the Family Medical History Questionnaire
At baseline an Year 1
Fitness Level
Time Frame: At baseline an Year 1
Measured by volitional oxygen intake, otherwise known as VO2 max, using the Ebbeling Treadmill Test (a submaximal walking test)
At baseline an Year 1
Diet
Time Frame: At baseline an Year 1
Measured using the Mindful Eating Questionnaire and the 3 Factor Eating Questionnaire
At baseline an Year 1
Dietary Intake
Time Frame: At baseline an Year 1
The RxFood App will be used to measure dietary intake over 3 full days.
At baseline an Year 1
Physical Activity
Time Frame: At baseline an Year 1
Measured using the International Physical Activity Questionnaire - Short form (IPAQ-S)
At baseline an Year 1
Physical Activity Assessment
Time Frame: At baseline an Year 1
An Actigraph activity monitor will be used to measure physical activity for 7 days, wtih participants asked to wear the monitor at all times.
At baseline an Year 1
Sleep Quality Assessment
Time Frame: At baseline and Year 1
Measured using the Pittsburgh Sleep Quality Index Questionnaire (PSQI), an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.
At baseline and Year 1
Sleep Assessment
Time Frame: At baseline and Year 1
An ActiGraph activity monitor will be used to measure sleep quality patterns for 7 days, wtih participants asked to wear the monitor at all times, including when they sleep.
At baseline and Year 1
Stress
Time Frame: At baseline and Year 1
The Perceived Stress Questionnaire (PSQ) will be completed to assess stressful life events and circumstances that tend to trigger or exacerbate disease symptoms.
At baseline and Year 1
Cognition Assessment
Time Frame: At baseline and Year 1
The Montreal Cognitive Assessment Score (MoCA) will be used to give insight into how participants mentally process information.
At baseline and Year 1
Body Weight
Time Frame: At baseline and at Year 1
Body weight will be measured.
At baseline and at Year 1
Body Mass Index (BMI)
Time Frame: At baseline and at Year 1
Body Mass Index will be measured
At baseline and at Year 1
Waist circumference
Time Frame: At baseline and at Year 1
Waist circumference will be measured
At baseline and at Year 1
Blood Pressure
Time Frame: At baseline and at Year 1
Blood pressure while awake, while asleep, and total will be measured using an ambulatory blood pressure monitor, worn for 3 consecutive days.
At baseline and at Year 1
Frailty
Time Frame: At baseline and at Year 1
The Short Physical Performance Battery (balance test, gait speed, and chair stand) and handgrip strength with be collected to measure frailty.
At baseline and at Year 1
Facility Usage
Time Frame: At baseline and at Year 1
Participants will complete a questionnaire on attendance in hours per week, and # of times per week, and specific program/facility usage at the Wellness Institute. The Wellness Institute swipe data will be used to record the number of times swiped per week and per month since joining.
At baseline and at Year 1
Cholesterol
Time Frame: At baseline and at Year 1
Total cholesterol, HDL-C, LDL-C, triglycerides, total cholesterol/HDL ratio
At baseline and at Year 1
HbA1c
Time Frame: At baseline and at Year 1
Hemoglobin A1C
At baseline and at Year 1
eGFR
Time Frame: At baseline and at Year 1
Estimated glomerular filtration rate.
At baseline and at Year 1
uACR
Time Frame: At baseline and at Year 1
Urine albumin to creatinine ratio
At baseline and at Year 1
10-Year Risk of Cardiovascular Disease
Time Frame: At baseline and at Year 1
Measured using the Framingham Risk Score
At baseline and at Year 1
Cardiovascular Assessment
Time Frame: At baseline and at Year 1
Identification of Metabolic Syndrome and the Framingham Risk Score will be measured.
At baseline and at Year 1
Body Composition
Time Frame: At baseline and at Year 1
DEXA scan measurements including total mass, fat mass, lean mass, % fat, visceral adipose tissue, total body bone mineral density), and relative skeletal muscle index (RSMI) will be collected.
At baseline and at Year 1
Social Determinants of Health
Time Frame: At baseline and at Year 1
Access to general medical and dental care, postal code, household income, education level and marital status will be collected.
At baseline and at Year 1
Wellbeing - Quality of Life
Time Frame: At baseline and at Year 1
the EQ-5D-5L will be collected to measure quality of life.
At baseline and at Year 1
Wellbeing - Loneliness
Time Frame: At baseline and at Year 1
The UCLA Loneliness Scale will be sued to measure loneliness.
At baseline and at Year 1
Wellbeing - Life Satisfaction
Time Frame: At baseline and at Year 1
The Satisfaction With Life Scale will be used to measure life satisfaction
At baseline and at Year 1
Wellbeing - Self-efficacy
Time Frame: At baseline and at Year 1
The Multidimensional Health Locus of Control (MHLC) Scale Form A will be used to measure self-efficacy
At baseline and at Year 1
Wellbeing - Depression
Time Frame: At baseline and at Year 1
The Center for Epidemiologic Studies Short Depression Scale (CES-D-10) will be used to measure depression
At baseline and at Year 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Claudio Rigatto, MD, University of Manitoba

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2024

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

May 1, 2026

Study Registration Dates

First Submitted

October 20, 2023

First Submitted That Met QC Criteria

October 20, 2023

First Posted (Actual)

October 25, 2023

Study Record Updates

Last Update Posted (Actual)

November 28, 2025

Last Update Submitted That Met QC Criteria

November 21, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • HS25790 (H2022:393)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Aging

Subscribe